Cefprozil Anhydrous, (E)-

CHEMBL276568 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
389.4 g/mol
LogP
-1.4
Phase
4

The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.

น้ำหนักโมเลกุล

389.4000 g/mol

LogP

-1.40

TPSA

158.00 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1

InChI

InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1

Molecular Formula

C18H19N3O5S

HBD / HBA

4 / 7

พันธะที่หมุนได้

5

อะตอมหนัก

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefprozil Anhydrous, (E)- is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL276568. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5281006. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.